Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Liver Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Liver Cancer
    TopAbstracts in Liver Cancer 11/27/2008 - (DGNews)
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    TopAbstracts in Liver Cancer 11/13/2008 - (DGNews)
    Sorafenib Improves Markers of Survival in Patients With Liver Cancer: Presented at AASLD - (DGDispatch)
    TopAbstracts in Liver Cancer 10/30/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Liver Cancer

    Webcasts/CME archive

     Recent cases - Liver Cancer
      Complete Clinical Response of Metastatic Hepatocellular Carcinoma to Sorafenib in a Patient with Hemochromatosis: A Case Report
      Isolated Metastatic Extremity Liposarcoma to the Liver, an Uncommon and Transient Finding
      Primary Carcinoid Tumors of the Liver
      Acute Liver Failure Due to Primary Angiosarcoma : A Case Report and Review of Literature
      Primary Hepatic Lymphoma Presenting as Fulminant Hepatic Failure With Hyperferritinemia: A Case Report

      Cases archive
        




      my personal edition > liver cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Sorafenib Effective in Patients With Liver Cancer Infected With Hepatitis B: Presented at ESMO

      By Ed Susman

      STOCKHOLM, Sweden -- September 14, 2008 -- Sorafenib therapy for patients with hepatocellular carcinoma who are infected with hepatitis B virus appears to be as effective in treating cancer as it is in patients without the hepatitis B infection, according to research presented here at the 33rd European Society for Medical Oncology Congress (ESMO).

      "The results of this subset analysis support the utility of sorafenib in a broad range of patients with different etiologic classes of hepatocellular carcinoma," said Zhong-Zhen Guan, MD, Sun Yat-Sen University Cancer Center, Guangzhou, China, speaking here on September 13 at a discussion of his poster presentation.

      Dr. Guan and colleagues dissected data from a multinational, double-blind, placebo-controlled trial conducted in patients from the Asia-Pacific region with advanced hepatocellular carcinoma. In that study, sorafenib 400 mg twice/day significantly prolonged overall survival and time to progression compared with placebo.

      The researchers identified 165 patients who were positive for hepatitis B virus, 106 of whom had been assigned to sorafenib and 59 of whom had been assigned to placebo in the phase 3 trial. Overall, 226 patients in the trial were all from China, South Korea, and Taiwan.

      "Among hepatitis B virus-positive patients, overall survival and time to progression were longer with sorafenib than with placebo of 30% and 48%, respectively," Dr. Guan reported.

      Overall survival in the total group studied was 6.5 months if the patients were on sorafenib, 4.2 months if they were assigned to placebo. If patients were infected with hepatitis B virus and were receiving sorafenib, their survival was 5.9 months. If patients were infected with hepatitis B virus and had been assigned to placebo, however, their overall survival was only 4.1 months.

      Time to progression was 2.7 months among patients infected with hepatitis B virus receiving sorafenib and 1.4 months if these patients were on placebo.

      "Sorafenib was effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, irrespective of the hepatitis B virus status," Dr. Guan concluded.

      Funding for this study was provided by Bayer AG and Onyx Pharmaceuticals, Inc.

      [Presentation title: Sorafenib Is Effective in Hepatitis B-Positive Patients With Hepatocellular Carcinoma (HCC): Subgroup Analysis of a Randomized, Doubleblind, Phase III Trial Performed in the Asia-Pacific Region. Abstract 512PD]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send